mircera solution for injection in pre filled syringe 200mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe 150mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe 100mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe 75mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe 50mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe, 30mcg/0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
mircera solution for injection in pre filled syringe 120mcg0.3ml
roche (malaysia) sdn. bhd. - methoxy polyethylene glycol-epoetin beta -
hemlibra 150 mgml
roche pharmaceuticals (israel) ltd - emicizumab - solution for injection - emicizumab 150 mg / 1 ml - emicizumab - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.
hemlibra 30 mgml
roche pharmaceuticals (israel) ltd - emicizumab - solution for injection - emicizumab 30 mg / 1 ml - emicizumab - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.
cellcept 500 mg
roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.